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A novel therapy for Epstein-Barr virus (EBV)-positive tumors involves the intentional induction of the lytic
form of EBV infection combined with ganciclovir (GCV) treatment. Virally encoded kinases (thymidine kinase
and BGLF4) which are expressed only during the lytic form of infection convert GCV (a nucleoside analogue)
into its active, cytotoxic form. However, tightly latent EBV infection in B cells has made it difficult to identify
drugs that can be used clinically to induce lytic viral infection in B-cell lymphomas. Here we demonstrate that
gemcitabine and doxorubicin (but not 5-azacytidine, cis-platinum, or 5-fluorouracil) induce lytic EBV infection
in EBV-transformed B cells in vitro and in vivo. Gemcitabine and doxorubicin both activated transcription
from the promoters of the two viral immediate-early genes, BZLF1 and BRLF1, in EBV-negative B cells. This
effect required the EGR-1 motif in the BRLF1 promoter and the CRE (ZII) and MEF-2D (ZI) binding sites in
the BZLF1 promoter. GCV enhanced cell killing by gemcitabine or doxorubicin in lymphoblastoid cells
transformed with wild-type EBV, but not in lymphoblastoid cells transformed by a mutant virus (with a
deletion in the BZLF1 immediate-early gene) that is unable to enter the lytic form of infection. Most impor-
tantly, the combination of gemcitabine or doxorubicin and GCV was significantly more effective for the
inhibition of EBV-driven lymphoproliferative disease in SCID mice than chemotherapy alone. In contrast, the
combination of zidovudine and gemcitabine was no more effective than gemcitabine alone. These results
suggest that the addition of GCV to either gemcitabine- or doxorubicin-containing chemotherapy regimens may
enhance the therapeutic efficacy of these drugs for EBV-driven lymphoproliferative disease in patients.
Epstein-Barr virus (EBV) is a human herpesvirus with tro-
pism for B cells and epithelial cells that establishes a life-long
persistent infection in more than 90% of the world’s popula-
tion. The primary infection with the virus is usually asymptom-
atic but can result in the self-limiting disease infectious mono-
nucleosis. Long-term carriage of the virus is also implicated in
the development of certain malignancies. The EBV genome is
frequently present in African Burkitt’s lymphomas, Hodgkin’s
disease, and lymphoproliferative disease in immunosuppressed
patients as well as nasopharyngeal carcinomas and some gas-
tric carcinomas (31, 43). In addition, EBV is possibly present in
a subset of breast cancers (7), liver cancers (47), lung cancers,
colon cancers, and prostate cancers (25). The presence of the
EBV genome in certain malignancies could serve as a potential
target for novel antitumor therapies (4, 20, 21, 27, 30, 40, 52).
One potential therapeutic strategy that takes advantage of
the EBV genome in tumor cells involves induction of the lytic
form of EBV infection in tumor cells, followed by administra-
tion of the nucleoside analogue ganciclovir (GCV). Like all
herpesviruses, EBV manifests two distinct phases in its life
cycle: latency and lytic replication. During latency, EBV ex-
presses a limited number of viral genes, which are involved in
tasks such as stimulating cell proliferation, inhibiting apopto-
sis, blocking viral lytic replication, and assuring accurate and
equal partitioning of the episomal viral genome to daughter
cells (31, 43). However, during the lytic replication phase of the
EBV life cycle, many more viral genes are expressed which
encode proteins involved in viral DNA replication and viral
particle synthesis. In addition, during the lytic form of infec-
tion, two virally encoded kinases, the EBV thymidine kinase
(EBV-TK) and the BGLF4 gene product, which phosphorylate
the prodrug GCV and convert it into its active cytotoxic form
(11, 33, 37, 41, 53), are expressed. Phosphorylated GCV inhib-
its not only the virally encoded DNA polymerase but also the
cellular DNA polymerase, leading to premature termination of
the nascent DNA and cell death (14, 23, 34). In addition,
phosphorylated GCV can be transferred to adjacent cells, thus
inducing “bystander” killing (23). Lytic EBV infection also
confers sensitivity to the cytotoxic effects of zidovudine (AZT),
possibly by inducing AZT phosphorylation (10, 28, 41, 52).
However, GCV and AZT are not generally effective for treat-
ing EBV-positive tumors because most tumor cells are infected
with the latent form of EBV and therefore do not express the
kinases which activate these drugs.
Thus, it is necessary to first convert the latent form of EBV
infection in tumor cells into the lytic form in order for GCV (or
AZT) treatment to be successful (11, 41, 53). The switch from
latent to lytic infection in host cells requires activation of the
two EBV immediate-early (IE) genes, BZLF1 and BRLF1,
which are not expressed during the latent form of infection.
BZLF1 and BRLF1 both encode transcriptional activators,
and together these proteins induce transcription of the entire
lytic viral gene program (31, 43). Previous studies showed that
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certain chemotherapy agents (fluorouracil [5-FU] and cis-plat-
inum) efficiently induce a lytic infection in EBV-positive epi-
thelial cell tumors in vivo and in vitro and that the addition of
GCV greatly enhances the ability of both 5-FU and cis-plati-
num to inhibit NPC tumor growth in nude mice (20). However,
EBV infection is primarily latent in B cells (in contrast to
epithelial cells, in which the virus infection is often lytic), and
consequently it has been more difficult to identify agents that
can efficiently induce a lytic EBV infection in B-cell tumors.
Although -irradiation induces lytic EBV infection and expres-
sion of the viral TK in EBV-positive lymphoblastoid cell lines
(LCLs) both in vitro and in vivo (45, 52) and might be useful
for treating localized EBV-positive lymphomas combined with
GCV, this method cannot be used to treat widely disseminated
EBV-positive B-cell lymphomas.
For this paper, we have examined the ability of various
chemotherapy or demethylating agents to induce a lytic EBV
infection in B cells and have studied the mechanism for the
lytic induction effect. We demonstrate that doxorubicin and
gemcitabine (but not cis-platinum, 5-FU, or 5-azacytidine) in-
duce lytic EBV infection in LCLs both in vitro and in vivo. The
induction of lytic EBV infection by these agents requires sev-
eral differential signal transduction pathways, including cellu-
lar stress mitogen-activated protein kinase (MAPK) p38, phos-
phatidylinositol 3-kinase (PI3 kinase), and MEK, but not
cellular apoptosis per se. In addition, we show that the induc-
tion of lytic infection by both doxorubicin and gemcitabine is
mediated through activation of the two viral IE genes (BZLF1
and BRLF1) and that this activation requires specific transcrip-
tion factor binding motifs (cyclic AMP-responsive element
[CRE], MEF2D, and EGR-1) in the promoters of these genes.
Furthermore, we demonstrate that chemotherapy and GCV
synergistically kill EBV-positive LCLs transformed by wild-
type EBV, but GCV does not enhance the killing effect of
chemotherapy in LCLs that cannot enter the lytic form of viral
infection due to a deletion in the viral BZLF1 gene. Finally, we
demonstrate that treatment of EBV-positive lymphoblastoid
tumors in SCID mice with chemotherapy and GCV together is
much more effective than either chemotherapy or GCV alone.
However, the combination of AZT and gemcitabine was no
more effective than gemcitabine alone. Our data suggest that
GCV may enhance the therapeutic effect of certain chemo-
therapy agents for treating EBV-associated lymphoprolifera-
tive disease.
MATERIALS AND METHODS
Cell lines. DG75 cells are an EBV-negative BL cell line. LCL-1 and LCL-2
were obtained by transforming human B cells with the B95-8 strain of EBV.
LCL-3 (wild-type) and an LCL-BZLF1 knockout (LCL-Z-KO) were established
from B cells from one individual infected with the wild-type B95-8 strain of the
EBV genome containing an inserted green fluorescent protein (GFP) gene or a
B95-8 virus (containing the GFP gene) with a deletion in the BZLF1 gene. The
wild-type and BZLF1 knockout GFP-positive viruses were constructed by use of
BAC technology as previously described (19). Raji is an EBV-positive Burkitt’s
lymphoma cell line. BL30 is an EBV-negative Burkitt’s lymphoma cell line.
BL30-EBV was established from BL-30 cells infected with the wild-type B95-8
strain of the EBV genome containing an inserted GFP gene. The culture me-
dium used was RPMI medium with 10% fetal bovine serum.
EBV promoter plasmids. Plasmid RpCAT contains the BRLF1 IE promoter
(Rp) sequences (from 962 to 5 relative to the mRNA start site) linked to the
heterologous reporter gene, chloramphenicol acetyltransferase (CAT), in a pBS
phagemid vector (Stratagene) (54). RpCAT (Zif) contains Rp sequences (from
962 to 5) with two site-directed mutations which delete the upstream (posi-
tions 125 to 131) and downstream (positions 42 to 44) Zif268 (EGR-1) binding
sites (55). Plasmid ZpCAT contains the BZLF1 IE promoter (Zp) (from 221
to 12 relative to the mRNA start site) linked to CAT (22). Plasmid ZpCAT
(ZIA/B) contains Zp sequences with two of the ZI motifs, ZIA and ZIB
(previously shown to bind to MEF2D as well as Sp1/3) (46), mutated as previ-
ously described (22). ZpCAT (ZII) contains Zp sequences with a site-directed
mutation in the ZII (CRE) site (22).
Lytic induction assays. LCLs were treated with either 5-azacytidine (1 or 2.5
M) (Sigma Chemical Co.), 5-FU (5 g/ml) (Pharmacia Upjohn Co.), cis-
platinum (1 g/ml) (American Pharmaceutical Partners, Inc.), doxorubicin (0.2
M) (Sigma Chemical Co.), or gemcitabine (1 g/ml) (Eli Lilly and Company)
for 3 to 5 days. Western blot analysis was performed as previously described (3),
using anti-BMRF1 (1:100) (Capricon), anti-BZLF1 (1:100) (Argene), anti-
BRLF1 (1:100) (Argene), and -actin (1:5,000) (Sigma Chemical Co.) antibodies
and an ECL detection kit (Amersham Pharmacia). Anti-LMP1 (1:100) (DAKO)
and anti-EBNA2 (1:100) (DAKO) antibodies were used to detect the expression
of LMP1 and EBNA2. Cell killing was determined by trypan blue exclusion
before harvesting for Western blot analysis.
Immunofluorescence. LCL-1 cells treated with no drug or gemcitabine (1
g/ml) for 3 days were fixed in cold 50% acetone–50% methanol for 10 min at
20°C. Cells were then stained with anti-BMRF1 antibody (1:500) (Argene) or
an isotype control antibody for 60 min at room temperature. BMRF1 staining
was visualized with fluorescein isothiocyanate-conjugated goat anti-mouse im-
munoglobulin G antibody (1:100) (Sigma) by fluorescence microscopy. DAPI
(4,6-diamidino-2-phenylindole) staining was also performed to visualize cell
nuclei.
Examination of signal transduction pathways. LCLs were pretreated for 1 h
with either no agent, PI3 kinase inhibitor LY294002 (15 M), p38 MAPK
inhibitor SB202190 (20 M), MEK inhibitor PD98059 (50 M), or caspase
pan-inhibitor Z-VAD-fmk (50 M) (all from Calbiochem). Cells were then
treated for 72 h with or without gemcitabine (1 g/ml) or doxorubicin (0.2 M)
in the presence or absence of the inhibitors above and were harvested for
immunoblot analysis of BMRF1, BZLF1, and BRLF1 expression.
Reporter gene assays. Plasmid DNA was purified by use of a Qiagen kit as
described by the manufacturer. DNA was transfected into EBV-negative DG75
cells by electroporation at 1,500 V with a Zapper electroporation unit (Medical
Electronics Shop, University of Wisconsin) using 5 g of DNA. Transfected cells
were then treated with or without doxorubicin (0.2 M) or gemcitabine (1 g/ml)
12 h later. Cell extracts were prepared at 72 h postchemotherapy and incubated
at 37°C with [14C]chloramphenicol in the presence of acetyl coenzyme A, as
described previously (24). The percent acetylation of chloramphenicol was quan-
tified by thin-layer chromatography followed by PhosphorImager screening (Mo-
lecular Dynamics).
In vitro cell killing studies with chemotherapy and GCV. LCL-3 and LCL-
Z-KO cells were treated with no drug; doxorubicin (0.05 M), gemcitabine (1
g/ml), or GCV (10 g/ml) (Warner-Lambert Co.) alone; or doxorubicin or
gemcitabine combined with GCV. Cell killing was determined by trypan blue
exclusion at 8 days posttreatment.
In vivo tumor studies. All animal experiments were conducted in accordance
with the guidelines of the Animal Care Committee. LCL-1 cells (5  107) were
implanted subcutaneously into the flanks of 6-week-old SCID mice. For deter-
mination of whether chemotherapy can induce lytic EBV infection in vivo, mice
with tumors were treated with no drug or one dose of gemcitabine (60 mg/kg of
body weight administered intraperitoneally [i.p.]), doxorubicin (10 mg/kg of body
weight administered i.p.), or 5-azacytidine (50 mg/kg of body weight). Seventy-
two hours later, mice were euthanized and tumors were removed surgically.
Tumors were processed as previously described (52), and protein extracts from
tumors were subjected to Western blot analysis as described above.
For tumor treatment studies, mice were treated (at 8 days postinjection) with
no drug (eight tumors), one dose of gemcitabine (60 mg/kg of body weight
administered i.p.) (eight tumors) or doxil (2 mg/kg of body weight administered
intravenously) (Ben Venue Laboratories, Inc.) alone, GCV (100 mg/kg of body
weight administered i.p. twice a day for 5 days) alone, or the combination of
GCV and one dose of gemcitabine (eight tumors) or GCV and one dose of
doxorubicin (eight tumors). The mice were examined and tumor measurements
were obtained three times per week after drug treatment was initiated. In a
separate study, mice received either AZT alone (50 mg/kg/day administered i.p.
for 5 days) (Catalytica Pharmaceuticals, Inc.), one dose of gemcitabine alone (60
mg/kg of body weight administered i.p.), or gemcitabine followed by 5 days of
AZT. Mice were euthanized when the tumor size exceeded 1 cm. Statistical
analysis was performed by using the t test.
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RESULTS
Gemcitabine and doxorubicin induce lytic EBV infection in
EBV-immortalized lymphoblastoid cells in vitro. EBV-trans-
formed B cells (lymphoblastoid cells) are usually tightly latent.
However, it is known that demethylation of the viral genome
induces lytic EBV genome expression in a subset of Burkitt’s
lymphoma cell lines (6), and it was previously shown that 5-FU
and cis-platinum induce lytic EBV infection in epithelial cell
lines (20). We therefore examined the ability of various che-
motherapy agents (5-FU, cis-platinum, gemcitabine, and doxo-
rubicin) and a demethylating agent (5-azacytidine) to induce
lytic EBV infection in three different LCLs. Cells were treated
for 5 days with the various agents and then the expression level
of several different lytic EBV proteins was quantitated by im-
munoblot analysis. As shown in Fig. 1A, both gemcitabine and
doxorubicin induced the expression of lytic EBV proteins in
each of three independently derived LCLs. However, 5-azacy-
tidine, 5-FU, and cis-platinum did not significantly activate
lytic EBV infection in any of the three LCLs. Interestingly,
each of the chemotherapy drugs produced a similar level of
toxicity in the LCL-1 line (Fig. 1B), suggesting that cell killing
per se is not sufficient to induce the lytic form of EBV infec-
tion. LMP1 and EBNA2 expression was not significantly af-
fected by either doxorubicin or gemcitabine treatment of
LCL-1 cells (Fig. 1C), in contrast to the recently reported
effects of the cytotoxic drug cidofovir (1).
To investigate the proportion of cells that switched to the
lytic type of EBV infection upon treatment with gemcitabine,
we used immunofluorescence to detect expression of the viral
early antigen BMRF1. As shown in Fig. 1D, in the absence of
chemotherapy, very few LCL-1 cells expressed BMRF1. After
3 days of gemcitabine treatment, approximately 10% of the
LCL-1 cells expressed BMRF1; this number may be an under-
estimate due to poor antibody staining of chemotherapy-
treated cells.
In contrast to its lack of effect in lymphoblastoid cells, 5-aza-
cytidine efficiently induced lytic EBV gene expression in the
Raji Burkitt cell line (Fig. 2). Similar to the effects observed in
the LCLs, the induction of lytic EBV infection in Raji cells was
induced much more efficiently with gemcitabine and doxoru-
bicin than with 5-FU and cis-platinum. These results indicate
that agents which induce lytic EBV infections in epithelial
cells, or Burkitt lines, are not necessarily able to induce lytic
EBV infections in LCLs. Of the various agents tested, gemcit-
abine and doxorubicin were clearly the most effective drugs for
inducing lytic EBV infections in lymphoblastoid cells in vitro.
Inhibitors of PI3 kinase, p38 MAPK, and MEK block the
induction of lytic EBV infection by gemcitabine and doxoru-
bicin. Since previous reports suggested that the PI3 kinase, p38
MAPK, and MAPK/ERK pathways are required for the acti-
vation of lytic EBV infection by certain agents (2, 9, 16, 18, 20),
we examined the effects of specific inhibitors of PI3 kinase, p38
MAPK, and MEK on the induction of lytic EBV infection by
gemcitabine and doxorubicin. LCL-1 cells were pretreated for
1 h with PI3 kinase, p38 MAPK, or MEK inhibitors before the
addition of gemcitabine or doxorubicin, and 3 days later the
expression of various EBV lytic proteins was analyzed by im-
munoblotting. As shown in Fig. 3, LY294002 (PI3 kinase in-
hibitor), SB202190 (p38 MAPK inhibitor), and PD98059
(MEK inhibitor) each prevented the induction of lytic EBV
gene expression by both gemcitabine and doxorubicin. These
findings suggest that the PI3 kinase, p38 MAPK, and MEK
pathways may be involved in the induction of lytic EBV infec-
tion by gemcitabine and doxorubicin. However, the induction
of lytic EBV infection was not blocked by treatment with a
pan-caspase inhibitor (Z-VAD-fmk). Thus, apoptosis per se
does not appear to be required. Similar results were obtained
previously with regard to the signal transduction pathways re-
quired for cis-platinum and 5-FU induction of lytic EBV in-
fection in epithelial cell lines (20).
Gemcitabine and doxorubicin activate the two EBV IE pro-
moters (Rp and Zp) in EBV-negative DG75 cells. The immu-
noblot analysis shown in Fig. 1A indicated that gemcitabine
and doxorubicin both induce expression of the two EBV IE
proteins, BZLF1 and BRLF1. For determination of whether
these agents directly activate transcription of the BZLF1 (Zp)
and BRLF1 (Rp) promoters, EBV-negative B cells (DG75)
were transfected with reporter gene constructs containing the
wild-type Rp (RpCAT) or Zp (ZpCAT) promoters linked to
the CAT gene. In addition, constructs containing site-directed
mutations of transcription factor binding sites in each pro-
moter that are known to be important for the induction of Zp
and Rp by other stimuli were also examined for the ability to
be activated by chemotherapy. Treatment of DG75 cells with
either gemcitabine or doxorubicin significantly increased the
CAT activity derived from either the RpCAT or ZpCAT con-
struct (Fig. 4B), while having no effect on the promoterless
control construct (data not shown). Thus, both chemoagents
enhance the activity of the BZLF1 and BRLF1 promoters in
EBV-negative cells. To further define the promoter elements
required for chemotherapy induction of the BRLF1 promoter,
we examined whether two Zif268 (EGR-1) binding sites which
have previously been shown to be required for phorbol ester
activation of the promoter (55) are also required for chemo-
therapy activation by using an RpCAT construct missing the
two binding sites. As shown in Fig. 4B, neither gemcitabine nor
doxorubicin significantly activated the BRLF1 promoter in the
absence of the binding sites, indicating that these sites are
important for chemotherapy activation. We also examined the
importance of two ZI sites (which bind to MEF2D and Sp1/3)
(8, 35, 46), as well as the ZII (CRE) site (which binds to
CREB, ATF-1, ATF-2, and c-Jun) (2, 51), in the BZLF1 pro-
moter for chemotherapy induction, since these motifs have
been previously shown to be required for the induction of
BZLF1 transcription by phorbol esters as well as by calcium
ionophores (46). Neither the ZpCAT (ZIA/B) construct,
which is missing the ZIA and ZIB binding sites, nor the
ZpCAT (ZII) construct, which is missing the ZII (CRE) site,
could be activated by either chemotherapy agent (Fig. 4).
These results indicate that chemotherapy activates the BRLF1
and BZLF1 promoters through the same transcription factor
binding sites that are required for other methods of lytic in-
duction.
The ability of GCV to enhance chemotherapy killing of EBV-
transformed B cells requires lytic EBV infection. Although it is
clear that lytically infected cells express virally encoded kinases
which can phosphorylate GCV, it has been somewhat contro-
versial whether EBV-dependent killing by GCV actually re-
quires the lytic form of infection (28). To further examine this




FIG. 1. Gemcitabine and doxorubicin induce lytic EBV infection in B cells in vitro. (A) EBV-positive lymphoblastoid cells derived from three
different hosts (LCL-1, LCL-2, and LCL-3 cells) were treated with 5-azacytidine (5-AZA; 2.5 M), 5-FU (5 g/ml), cis-platinum (CIS-PLAT; 1
g/ml), doxorubicin (DOXO; 0.2 M), or gemcitabine (GEM; 1 g/ml). Cells were harvested 5 days later and analyzed for expression of the
EBVIE proteins BZLF1 and BRLF1 or the viral early antigen BMRF1 by immunoblot analysis. The same blots were also probed with anti--actin
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issue, we immortalized B cells from the same host with either
wild-type (B95-8) virus (LCL-3 line) or a virus with a deletion
in the BZLF1 gene that can latently infect cells but is unable to
cause the lytic type of infection. These viruses were con-
structed as previously described (19). The wild-type LCL-3 line
and BZLF1 knockout (Z-KO) line were treated with GCV
alone, gemcitabine (Fig. 5A) or doxorubicin (Fig. 5B) alone, or
the combination of GCV and chemotherapy. The number of
surviving cells was determined by trypan blue staining at 8 days
posttreatment. As shown in Fig. 5, GCV alone was somewhat
more toxic in the wild-type LCL-3 cells than in the BZLF1
knockout cells, presumably reflecting the fact that this partic-
ular wild-type LCL contained some cells with the lytic form of
viral infection even in the absence of inducing agents (data not
shown). The cytotoxic effect of gemcitabine alone was similar
in the wild-type and BZLF1 knockout lines, whereas doxoru-
bicin was somewhat more toxic in the wild-type line. Most
importantly, however, while the addition of GCV clearly en-
hanced the killing effect of both gemcitabine and doxorubicin
in the wild-type LCLs, it had no effect on chemotherapy killing
in the cells that were immortalized with the BZLF1 knockout
virus. These results clearly indicate that the ability of GCV to
enhance chemotherapy-mediated killing of EBV-positive tu-
mor cells requires the lytic form of viral infection.
Gemcitabine and doxorubicin induce lytic EBV infection in
lymphomas in vivo. We next examined the ability of doxoru-
bicin, gemcitabine, or 5-azacytidine to induce lytic EBV infec-
tion in lymphomas in vivo. LCL-1 cells (5  107) were injected
subcutaneously into the flanks of SCID mice. After the devel-
opment of tumors, mice were treated with a single dose of
either 5-azacytidine (i.p), gemcitabine (i.p.), or doxorubicin
(i.p.) and then euthanized 72 h later. Tumors were analyzed by
immunoblotting for expression of the EBV IE protein BRLF1
or the early lytic protein BMRF1. As shown in Fig. 6, the
demethylating agent 5-azacytidine could not induce lytic EBV
infection in lymphomas derived from lymphoblastoid cells.
However, expression of the EBV IE protein BRLF1 and the
early protein BMRF1 was clearly induced by a single dose of
gemcitabine and doxorubicin. These results indicate that gem-
citabine and doxorubicin can both induce lytic EBV infection
in lymphomas at clinically relevant doses.
GCV enhances the therapeutic effect of gemcitabine and
doxorubicin in EBV-positive lymphoproliferative disease in
SCID mice. To determine whether GCV can enhance the ef-
ficacy of chemotherapy for EBV-driven lymphoproliferative
disease in vivo, we injected 5  107 LCL-1 cells subcutaneously
into the flanks of SCID mice and treated the mice 8 days after
cell injection with either no drug, GCV alone for 5 days, one
dose of gemcitabine alone, or one dose of gemcitabine fol-
lowed by a 5-day GCV treatment (Fig. 7A). In a separate
experiment, the effect of a single dose of doxorubicin (2 mg/kg
administered intravenously), with or without subsequent GCV
treatment, was also assessed (Fig. 7B). As shown in Fig. 7,
GCV alone produced some inhibition of EBV-driven lympho-
proliferation, presumably due to the small percentage of lym-
phoblastoid cells containing the lytic form of EBV infection.
Treatment with gemcitabine alone had only a small antitumor
effect, whereas doxorubicin alone, as expected, significantly
FIG. 2. Gemcitabine, doxorubicin, and 5-azacitidine induce lytic
EBV infection in Raji cells. EBV-positive Raji Burkitt’s lymphoma
cells, or LCL-1 cells, were treated with 5-azacytidine (5-AZA; 1 M),
5-FU (5 g/ml), cis-platinum (CIS-PLAT; 1 g/ml), doxorubicin
(DOXO; 0.2 M), or gemcitabine (GEM; 1 g/ml) and analyzed 5
days later for expression of the viral early antigen BMRF1 by immu-
noblot analysis.
FIG. 3. Induction of lytic EBV infection by gemcitabine and doxo-
rubicin requires activation of PI3 kinase, p38 kinase, and MEK path-
ways. LCL-1 cells were pretreated for 1 h with or without the indicated
inhibitors and then were treated with either gemcitabine or doxorubi-
cin. The cells were harvested 72 h later and analyzed for the EBV IE
and early proteins by immunoblot analysis.
antibody. (B) LCL-1 cells were treated with 5-azacytidine, 5-FU, cis-platinum, doxorubicin, or gemcitabine, and the percent cells surviving (relative
to untreated cells) was determined by trypan blue exclusion at 5 days posttreatment. (C) LMP1 and EBNA2 expression was assayed by Western
blotting with an EBV-negative (BL30) or EBV-positive (BL30-EBV) Burkitt’s lymphoma cell line or with untreated versus doxorubicin- or
gemcitabine-treated LCL-1 cells. (D) Expression of the lytic viral antigen BMRF1 was examined by immunofluorescence in untreated LCL-1 cells
or LCL-1 cells treated with gemcitabine for 3 days.
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inhibited growth. Most importantly, the lymphoproliferative
tumors in mice treated with gemcitabine or doxorubicin plus
GCV were significantly smaller than the tumors in mice
treated with gemcitabine (P 	 0.009) or doxorubicin (P 	
0.039) alone. In contrast, we did not find that the combination
of gemcitabine and AZT was significantly more effective than
either drug alone (Fig. 7C). Thus, although GCV and AZT
have both been reported to preferentially kill lytically infected
EBV-positive cells in vitro (41, 52), GCV was considerably
more effective than AZT for the treatment of EBV-associated
lymphoproliferative disease (in combination with chemother-
apy) in this mouse model.
DISCUSSION
EBV, a gammaherpesvirus with potent B-cell-transforming
activity, is linked to Burkitt’s lymphoma, Hodgkin’s lymphoma,
and lymphoproliferative diseases in immunosuppressed pa-
tients (31, 43). The persistent expression of certain EBV-en-
coded gene products is likely required for the continued
growth of many EBV-associated lymphomas. Although antivi-
ral therapy is effective for treating lytic EBV infection (for
example, oral hairy leukoplakia lesions), it has not been clearly
shown that antiviral agents have any therapeutic effect for
treatment of EBV-associated lymphoproliferative diseases,
which primarily contain the latent form of infection (13). How-
ever, in combination with strategies for inducing the lytic form
of EBV infection in tumor cells, the cytotoxic effects of certain
antiviral drugs, such as GCV, could potentially be used to kill
EBV-positive tumor cells. In this study, we have examined the
ability of various chemotherapy drugs, as well as 5-azacytidine,
to induce lytic EBV infection in EBV-positive lymphoblastoid
cells and have defined the mechanisms for the lytic-inducing
effects. Gemcitabine and doxorubicin were both shown to in-
FIG. 4. Doxorubicin and gemcitabine activate the two EBV IE
promoters (Rp and Zp) in EBV-negative DG75 cells. (A) Constructs
containing the wild-type or mutant BZLF1 (Zp-CAT) or BRLF1 (Rp-
CAT) promoters linked to the CAT gene were constructed as de-
scribed in Materials and Methods. Transcription factors known to bind
to the promoters are indicated. (B) EBV-negative DG75 cells were
transfected with 5 g of each promoter construct, as indicated, and
then were treated with no drug, doxorubicin, or gemcitabine for 72 h.
CAT assays were performed as described previously (24). The average
fold activation by each drug is shown.
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duce lytic EBV infection in lymphoblastoid cells through acti-
vation of the promoters driving the two viral IE genes, BZLF1
and BRLF1. Furthermore, the addition of GCV to either gem-
citabine or doxorubicin greatly enhanced the ability of these
drugs to inhibit the growth of EBV-driven lymphoproliferative
disease in SCID mice. In contrast, AZT did not enhance the
antitumor effect of gemcitabine in this mouse model of an
EBV-positive lymphoma.
The switch from latent to lytic EBV infection in host cells is
mediated by the transcriptional effects of the two EBV IE
proteins, BZLF1 and BRLF1, and overexpression of either one
of these proteins in latently infected cells is sufficient to induce
the lytic form of EBV infection (12, 15, 42, 44, 49, 56). In
latently infected B cells, the BZLF1 (Zp) and BRLF1 (Rp)
promoters are inactive. However, ligation of the B-cell recep-
tor (48), phorbol ester treatment (58), calcium ionophores
(17), transforming growth factor 1 (18), demethylating agents
(41), and agents which induce histone acetylation (38, 39, 52)
are known to activate expression of the BZLF1 and BRLF1 IE
promoters in at least a portion of EBV-positive B-cell lines. In
the case of the BZLF1 IE promoter (Zp), the two promoter
elements which appear to be essential for stimulation by most,
if not all, of these inducing factors are termed the ZI and ZII
motifs (46). Several of the ZI motifs are bound by the MEF2D
cellular transcription factor, as well as by Sp1/Sp3 (8, 35), and
MEF2D has been shown to be an important regulator of EBV
infection in host cells (26, 46). The ZII motif is a CRE site
which is bound by CREB, ATF-1, c-Jun, and ATF-2 (2, 51).
The results presented here indicate that the ability of both
gemcitabine and doxorubicin to activate BZLF1 transcription
in EBV-negative cells requires both the ZI and ZII binding
motifs of the BZLF1 promoter. Gemcitabine and doxorubicin
also activated the BRLF1 IE promoter in EBV-negative cells.
This effect was shown to require the presence of two EGR-1
(Zif268) binding sites in the promoter which were previously
shown to be important for phorbol ester-induced activation of
the promoter (55).
Our data also indicate that the ability of gemcitabine and
doxorubicin to induce lytic EBV gene expression requires sev-
eral different signal transduction pathways, including the PI3K,
p38 MAPK, and MEK pathways. These same pathways were
previously shown to be required for lytic viral induction fol-
lowing ligation of the B-cell receptor (2, 9, 16) as well as for
lytic induction induced by transforming growth factor 1 (18).
The requirement for the p38 MAPK stress pathway may reflect
the ability of this kinase to activate both the c-Jun and ATF-2
transcription factors (36, 50), which bind to the CRE site in the
BZLF1 promoter. In addition, it has been reported that at least
some members of the MEF2 family are activated by p38 kinase
phosphorylation (57). The treatment of cells with chemother-
apy agents has been shown to activate p38 kinase (5, 32), and
thus it is likely that activation of this pathway is at least par-
tially responsible for lytic EBV induction following chemother-
apy. In addition, doxorubicin has been reported to induce
activation of the cellular IE protein EGR-1, through both p38
FIG. 5. Synergistic killing between GCV and chemotherapy requires lytic EBV infection. EBV-positive LCL cells derived from the wild-type
virus (LCL-3) or a mutant virus with a deletion in the BZLF1 gene (LCL-Z-KO) were treated with GCV alone, gemcitabine alone (A), gemcitabine
plus GCV (A), doxorubicin alone (B), or doxorubicin plus GCV (B). Cell viability (relative to untreated cells) was determined 8 days later by trypan
blue exclusion.
FIG. 6. Doxorubicin and gemcitabine induce lytic EBV infection in
lymphomas in vivo. Lymphomas were made by injecting mice subcu-
taneously in the flanks with LCL-1 cells. Mice with tumors were
treated with no drug or a single i.p. dose of 5-azacytidine, doxorubicin,
or gemcitabine. Tumors were harvested 72 h after treatment and
analyzed for expression of the EBV IE protein BRLF1 and the early
viral protein BMRF1 by immunoblot analysis.
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FIG. 7. GCV enhances the therapeutic effect of gemcitabine and doxorubicin on EBV-driven lymphoproliferative disease in mice. EBV-positive
lymphoblastoid cells (5  107 LCL-1 cells) were implanted subcutaneously into the flanks of SCID mice. Tumors (eight tumors in each group) were
treated 8 days after injection with either no drug, GCV alone, gemcitabine alone or gemcitabine followed by 5 days of GCV treatment (A),
doxorubicin with or without GCV treatment (B), or AZT alone, gemcitabine alone, or gemcitabine and AZT (C). Tumor volumes at different time
points (means 
 standard errors) are shown.
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kinase-dependent (5) and MEK-dependent (32) mechanisms,
and our results indicate that the ability of both doxorubicin and
gemcitabine to activate the BRLF1 IE promoters requires
EGR-1 binding motifs. Thus, chemotherapy is likely to induce
BZLF1 and BRLF1 transcription by activating several different
signal transduction pathways which have downstream activat-
ing effects on the cellular transcription factors binding to
EGR-1, CRE, and MEF2D binding motifs. However, apopto-
sis per se does not appear to be required, as a pan-caspase
inhibitor did not prevent lytic induction, nor is cell killing alone
sufficient, since cis-platinum and 5-FU were as toxic as gem-
citabine and doxorubicin in LCL-1 cells. The fact that gemcit-
abine (a pyrimidine analogue) and doxorubicin (which inter-
calates into DNA) have very different killing mechanisms
suggests that the exact mechanism of cell killing does not
predict the ability of different agents to induce lytic EBV in-
fection.
The data presented here also demonstrate that EBV-depen-
dent GCV toxicity requires the lytic form of viral infection.
This is not particularly surprising, since previous reports (40,
52) have suggested that lytically infected cells are more sus-
ceptible to GCV cytotoxicity and since it is known that virally
encoded kinases expressed only during the lytic form of EBV
infection (EBV TK and BGLF4) can confer GCV susceptibil-
ity (39, 41, 53). Nevertheless, the data presented here, for
which lymphoblastoid cells from the same host were immor-
talized with either a wild-type or lytic-defective (with a deletion
in BZLF1) virus, very clearly demonstrate that the ability of
GCV to enhance the cytotoxicity of chemotherapy requires the
lytic form of EBV infection. Thus, it is extremely unlikely that
sufficient GCV phosphorylation could be achieved to be clin-
ically useful in tumors containing completely latent EBV in-
fections. Nevertheless, certain tumors may contain enough
cells with the lytic form of EBV infection for GCV by itself to
have some clinical benefit (45). Although we and others have
previously shown that lytic EBV infection (or the EBV TK
alone) confers sensitivity to the cytotoxic effects of AZT in
vitro (41, 52), we were unable to demonstrate this effect here
with our mouse model of EBV-positive lymphomas. Neverthe-
less, it remains possible that AZT at a dose higher than that
used in this particular study might have had some benefit.
Although we have concentrated here on activating lytic gene
transcription from the endogenous EBV genome in tumor
cells, another approach for inducing lytic EBV infection in
tumors would be to introduce the BZLF1 or BRLF1 genes
under the control of a strong heterologous promoter by gene
delivery methods. It was recently shown that direct delivery of
the two EBV IE genes into nasopharyngeal carcinomas by
using adenovirus vectors induces lytic EBV gene expression in
the tumors and inhibits tumor growth (20). However, adeno-
virus delivery of the two EBV IE genes to B-cell lymphomas
would be limited by the fact that B cells express very little (if
any) of the major receptor (CAR) for adenovirus, although
this hurdle could potentially be overcome by the use of bispe-
cific antibody techniques (29). Nevertheless, drug-based strat-
egies for inducing lytic EBV infection in widely disseminated
EBV-induced lymphoproliferative disease are more likely to
be successful clinically than gene delivery strategies. Although
we and others have previously shown that gamma irradiation
can also induce lytic EBV infection in B-cell lymphomas (45,
52), the combination of gamma irradiation and GCV can be
used only for localized malignancies.
Another implication of the studies presented here is that the
ability of various chemotherapy drugs to induce lytic EBV
induction is clearly cell type dependent. While cis-platinum
and 5-FU were previously shown to be highly successful for
inducing lytic EBV infection in epithelial tumors, these drugs
did not effectively induce lytic EBV infection in EBV-immor-
talized lymphoblastoid cells. Likewise, although the demethy-
lating agent 5-azacytidine induces lytic EBV infection in cer-
tain Burkitt’s lymphoma cell lines (6) and treatment with
5-azacytidine has been suggested as a potential way to induce
lytic EBV infection in patient tumors (41), we did not find this
approach to be successful for inducing lytic EBV infection in
EBV-positive lymphoblastoid cells. Previous reports have
shown that sodium butyrate (which induces histone acetyla-
tion) effectively induces the lytic form of EBV infection in at
least some Burkitt’s lymphoma cells (39, 52), and the combi-
nation of butyrate and GCV to treat EBV lymphomas in pa-
tients is currently being studied (40). The data presented in this
report indicate that the addition of GCV to either gemcitab-
ine- or doxorubicin-containing regimens may be useful for
enhancing the efficacy of these agents for treating EBV-in-
duced lymphoproliferative disease in immunosuppressed pa-
tients, since these tumors have a similar pattern of EBV latent
gene expression (type III) as the lymphoblastoid cells used to
make tumors in SCID mice for this study. Whether EBV-
positive lymphomas containing other types of EBV latency,
such as type I Burkitt’s lymphomas, would also respond favor-
ably to the combination of GCV and gemcitabine or doxoru-
bicin needs to be further studied.
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